Literature DB >> 1830550

Cardiac hypertrophy and function in asymptomatic acromegaly.

D Morvan1, M Komajda, A Grimaldi, G Turpin, Y Grosgogeat.   

Abstract

Heart disease frequently occurs in advanced acromegaly. In order to investigate cardiac mass and function in acromegaly in the absence of obvious cardiac disease, we performed Doppler echocardiography in 15 asymptomatic acromegalic patients (six of them had systemic hypertension). The data were compared with those of a group of 10 age-matched controls. Left ventricular mass index (LVMI) was increased in acromegaly (110 +/- 32 vs 32 +/- 12 g m-2, P = 0.02), but shortening fraction and systolic time intervals did not differ. Mitral EF slope was decreased (80 +/- 21 vs 101 +/- 30 mms-1, P less than 0.02), while the duration of the isovolumic relaxation period (IRP) was increased (92 +/- 13 vs 69 +/- 16 ms, P less than 0.01). Hypertensive acromegalic patients (n = 6) had a higher LVMI than normotensive acromegalic patients (n = 9) (133 +/- 27 vs 94 +/- 24 g m-2, P = 0.02) and this was confirmed by a meta-analysis of data in the literature: the prevalence of hypertrophy was 76% in the presence of hypertension vs 50% in its absence, P less than 0.002. IRP was prolonged in normotensive acromegalic patients vs normal controls (90 +/- 11 vs 69 +/- 16 ms, P less than 0.01). In conclusion, subclinical cardiac abnormalities occur frequently in acromegaly in the absence of obvious heart disease, and hypertrophy is observed in asymptomatic hypertensive acromegaly. Moreover, diastolic abnormalities are found in asymptomatic acromegaly and could be caused by several heart-related factors.

Entities:  

Mesh:

Year:  1991        PMID: 1830550

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  8 in total

1.  Left ventricular volume and mass in children on growth hormone therapy compared with untreated children.

Authors:  D Heuschmann; O Butenandt; M Vogel
Journal:  Eur J Pediatr       Date:  1996-02       Impact factor: 3.183

2.  Atrial conduction times and left atrium mechanical functions in patients with active acromegaly.

Authors:  A Ilter; A Kırış; Ş Kaplan; M Kutlu; M Şahin; C Erem; N Civan; F Kangül
Journal:  Endocrine       Date:  2014-07-15       Impact factor: 3.633

3.  Effects of somatostatin analogues on acromegalic cardiomyopathy: results from a prospective study using cardiac magnetic resonance.

Authors:  F Bogazzi; M Lombardi; E Strata; G Aquaro; M Lombardi; C Urbani; V Di Bello; C Cosci; C Sardella; E Talini; E Martino
Journal:  J Endocrinol Invest       Date:  2010-02       Impact factor: 4.256

4.  Left ventricular synchronicity is impaired in patients with active acromegaly.

Authors:  Abdulkadir Kırış; Cihangir Erem; Oğuzhan Ekrem Turan; Nadim Civan; Gülhanım Kırış; Irfan Nuhoğlu; Abdulselam Ilter; Halil Onder Ersöz; Merih Kutlu
Journal:  Endocrine       Date:  2012-12-20       Impact factor: 3.633

5.  The GH/IGF-1 Axis and Heart Failure.

Authors:  Graziella Castellano; Flora Affuso; Pasquale Di Conza; Serafino Fazio
Journal:  Curr Cardiol Rev       Date:  2009-08

6.  Cardiovascular effects of high-dose growth hormone treatment in growth hormone-deficient children.

Authors:  R Crepaz; W Pitscheider; G Radetti; C Paganini; L Gentili; G Morini; E Braito; G Mengarda
Journal:  Pediatr Cardiol       Date:  1995 Sep-Oct       Impact factor: 1.655

7.  Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study.

Authors:  G Lombardi; A Colao; P Marzullo; B Biondi; E Palmieri; S Fazio
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

Review 8.  Cardiovascular effects of growth hormone.

Authors:  W J Brickman; B L Silverman
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.925

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.